Innovotech Inc. (TSXV: IOT) has announced its intention to obtain a stock quotation in the United States on the OTCQB Venture Market, an over-the-counter market operated by OTC Markets Group. The move is designed to enhance the company's visibility to the investment community and make its shares more accessible to retail and institutional investors in the United States, while also aiming to increase liquidity.
The OTCQB quotation will operate in parallel with Innovotech's primary listing on the TSX Venture Exchange in Canada. According to the company, the OTCQB listing is expected to impose no additional material compliance or reporting requirements. As a foreign private issuer, Innovotech will continue to meet its existing primary market disclosure obligations on SEDAR+, which satisfy OTC market requirements under established foreign issuer exemptions. To be considered for admission to the OTCQB, companies must meet certain financial standards, be current in their reporting obligations, and undergo an annual verification and management certification process.
In conjunction with the OTCQB listing, Innovotech will also apply for eligibility with the Depository Trust Company (DTC). DTC eligibility enables simplified electronic clearing and settlement of the company's common shares for U.S. investors, further streamlining the trading process.
Innovotech Inc. is a Canadian boutique contract research organization specializing in advanced laboratory services and the commercialization of proprietary technologies. A leader in biofilm science, the company provides expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions. Among its key products is the widely used MBEC Assay® kit for high-throughput antimicrobial and antibiotic testing. Innovotech serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards, such as those of the U.S. Food and Drug Administration and Health Canada, through its ISO-certified and GMP-accredited laboratories. More information about the company is available at https://www.innovotech.ca.
The company's announcement comes as it seeks to broaden its investor base and improve trading liquidity. By listing on the OTCQB, Innovotech expects to attract greater attention from U.S. investors who may find it more convenient to trade shares on a U.S.-based market. The OTCQB is known for providing transparent trading and efficient access for investors in small and mid-cap companies.
This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; and the company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The company undertakes no obligation to publicly make or update any forward-looking statements, except as required by applicable law.
